|
OmniComm’s TrialMasterTM EDC Solution Selected by Leading Medical
Device Manufacturer for Phase IV Cardiovascular Device Study
Long Term Customers Continue to Propel OmniComm’s Fast-Paced Growth
Fort Lauderdale, FL, November 17, 2009 - OmniComm Systems, Inc.
(OTC: OMCM.OB), one of the fastest growing companies in the
EDC marketplace, announced today that a leader in the medical device industry has
selected OmniComm’s TrialMaster EDC solution for the data capture of a Phase IV
cardiovascular study. The 24-months, 7-site study will enroll 100 subjects.
"We look forward to continuing our successful collaboration with this device company",
remarked Stephen Johnson, COO of OmniComm Systems. "Our flagship EDC solution, TrialMaster,
has already proven to be an efficient and reliable data capture system for 12 of
this customer’s studies during the past 5 years. This is proof positive that the
high quality of our EDC solutions and our outstanding customer service continue
to generate the high percentage of return business needed to sustain our current
rate of growth."
About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com)
provides customer-driven Internet solutions to pharmaceutical, biotechnology, research
and medical device organizations that conduct life changing clinical trial research.
OmniComm's growing base of satisfied customers is a direct result of the company's
commitment to deliver products and services that ensure ease of use, faster study
build, ease of integration and better performance. OmniComm's client intuitive pricing
model allows companies that range from small, to mid-size to large scale institutions
to safely and efficiently capitalize on their clinical research investments. OmniComm
Systems, Inc has U.S. headquarters in Fort Lauderdale, FL and European headquarters
in Bonn, Germany, with satellite offices in New Jersey, the United Kingdom, and
Russia as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Safe Harbor Disclaimer Statements made by OmniComm included in this release may
constitute forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties
such as the Company's ability to obtain new contracts and accurately estimate net
revenues due to uncertain regulatory guidance, variability in size, scope and duration
of projects, and internal issues at the sponsoring client, integration of acquisitions,
competitive factors, technological development, and market demand. As a result,
actual results may differ materially from any financial outlooks stated herein.
Further information on potential factors that could affect the Company's financial
results can be found in the Company's Reports on Form 10-K and 10-Q filed with the
Securities and Exchange Commission. The Company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new information, future
events, or otherwise.
CONTACT: Stephen Johnson at: + 1 954-377-1726
Back
|
